40 mg\/ml solution for injection in a vial of
aflibercept<\/p>\n\n\n\n
Eylea is a solution that is injected into the eye to treat eye diseases in adults called<\/p>\n\n\n\n
Aflibercept, the active substance in Eylea, blocks the activity of a group of factors called vascular endothelial growth factor A (VEGF-A) and placental growth factor (P1GF).<\/p>\n\n\n\n
In patients with wet AMD and myopic CNV, an excess of these factors contributes to an abnormal formation of new blood vessels in the eye. These new blood vessels can lead to leakage of blood components in the eye and possibly cause damage to the tissues that are responsible for vision.
<\/p>\n\n\n\n
In patients with CRVO, a blockage occurs in the large blood vessel that transports blood from the retina (retina). VEGF levels increase as a reaction to this, which leads to leakage of fluid to the retina and thus causes swelling of the macula (the part of the retina that is responsible for detailed vision), which is called macular edema. When the macula swells up with fluid, the central vision becomes blurred.
<\/p>\n\n\n\n
In patients with BRVO, a blockage occurs in one or more branches of the large blood vessel that transports blood from the retina (retina). VEGF levels increase as a reaction to this, which leads to leakage of fluid to the retina and thus causes macular edema.
<\/p>\n\n\n\n
Diabetic macular edema is a swelling of the retina that affects patients with diabetes due to fluid leaking from the blood vessels in the macula ( yellow spot ). The macula is the part of the retina that is responsible for visual acuity. When the macula swells up with fluid, the vision becomes blurred.<\/p>\n\n\n\n
Eylea has been shown to stop the growth of new abnormal blood vessels in the eye that often leak fluid or bleed. Eylea can stabilize and in many cases improve the vision loss in connection with wet AMD, CRVO, BRVO, DME, and myopic CNV.
<\/p>\n\n\n\n
Talk to your doctor before receiving Eylea:<\/strong><\/p>\n\n\n\n Also, you must know that:<\/p>\n\n\n\n Systemic use of VEGF inhibitors, substances similar to those found in Eylea, is optionally associated with an increased risk of blood clots that block the blood vessels (arterial thromboembolic events) and can lead to myocardial infarction or stroke ( stroke ). There is a theoretical risk of such events after injection into the eye with Eylea. There are limited data on the safety of patients with CRVO, BRVO, DME, and myopic CNV who have had a stroke or a ministroke ( transient ischemic attack) or a heart attack in the last 6 months. If any of these apply to you, Eylea should be given with caution. There is only limited experience in the treatment of:<\/p>\n\n\n\n There is no experience in the treatment of:<\/p>\n\n\n\n If any of the above apply to you, your doctor will consider this lack of information when you are being treated with Eylea.<\/p>\n\n\n\n The use of Eylea in children and adolescents under 18 years of age has not been studied as wet AMD, CRVO, BRVO, DME, and myopic CNV mainly affect adults. Therefore, use in this age group is not relevant.<\/p>\n\n\n\n Tell your doctor if you are taking, have recently taken, or might take any other medicines.<\/p>\n\n\n\n After an injection of Eylea, you may experience temporary visual disturbances. Do not drive or use machines for as long as they remain.<\/p>\n\n\n\n This medicine contains less than 1 mmol (23 mg) sodium per dose unit, ie essentially ‘sodium-free’. A doctor with experience in giving eye injections will inject Eylea into the eye under aseptic (clean and sterile) conditions. The recommended dose is 2 mg aflibercept (50 microliters). Before injection, your doctor will use disinfectant eyewash to thoroughly clean your eye to prevent infection Your doctor will also give you local anesthetics to reduce or prevent the pain you may experience with injection one. Wet AMD<\/strong><\/em><\/p>\n\n\n\n Patients with wet AMD are treated with one injection a month for three consecutive months and then receive another injection after another two months. Your doctor will then decide if the treatment interval with an injection every two months can remain or if the interval should be gradually increased by 2 or 4 weeks if your condition has been stable. If your condition worsens, the interval between injections may be shortened.<\/p>\n\n\n\n If you do not experience any problems or have received any other advice from your doctor, you do not need to visit your doctor between injections. Macular edema secondary to RVO (branch vein occlusion or central vein occlusion)<\/strong><\/em><\/p>\n\n\n\n Your doctor will decide which treatment plan is most suitable for you. Your treatment will start with an Eylea injection once a month. The interval between two injections should not be shorter than one month. Your doctor may decide to stop your treatment with Eylea if you have no benefit from continuing treatment. Treatment should be continued with an injection once a month until the condition is stable. Three or more injections may be needed. Your doctor will monitor how you respond to treatment and can continue your treatment by gradually increasing the interval between injections to maintain a stable condition. If your condition begins to worsen with longer treatment intervals, your doctor may shorten the interval. Based on how you respond to the treatment, the doctor decides on follow-up examinations and treatments. Diabetic macular edema <\/em>(DME)<\/em><\/strong><\/p>\n\n\n\n Patients with DME are treated with one injection once a month for the first five doses and then one injection every two months. If you do not experience any problems or have received any other advice from your doctor, you do not need to visit your doctor between injections. After the first twelve months of treatment with Eylea, the treatment interval can be increased, based on the doctor’s assessment. The attending physician decides how often the control visits should take place. If it is determined that you will not benefit from continued treatment, your doctor may decide to stop treatment with Eylea. Myopia SK CNV<\/em><\/strong><\/p>\n\n\n\n Patients with myopic CNV are treated with a single injection. You will only receive an additional injection if your doctor’s examination shows that your condition has not improved. The interval between two injections should not be shorter than one month. If your condition disappears and then returns, your doctor may start treatment again. The attending physician decides how often the control visits should take place.<\/p>\n\n\n\n Book a new visit for examination and injection.<\/p>\n\n\n\n Contact a doctor before stopping treatment. If you have any further questions on the use of this product, ask your doctor.<\/p>\n\n\n\n Like all medicines, this medicine can cause side effects, although not everybody gets them. Allergic reactions<\/strong> (hypersensitivity) may occur. These can be serious and require you to contact your doctor immediately.<\/strong> When administering Eylea, there may be side effects that affect the eyes due to the injection procedure. Some of these can be serious<\/strong> and include blindness, a serious infection or inflammation of the eye<\/strong> ( endophthalmitis ), discharge, rupture or bleeding in the photosensitive layer in the back of the eye<\/strong> (retinal detachment or rupture ), clouding of the lens of the eye<\/strong> ( cataract ), bleeding in the eye<\/strong> (vitreous hemorrhage), the release of the gel-like substance in the eye from the retina<\/strong>(vitreous detachment) and increase in pressure in the eye<\/strong>, see section 2. These serious side effects affecting the eyes occurred in less than 1 in 1,900 injections in clinical trials. If you experience sudden deterioration of vision or an increase in pain and redness in the eye after injection, you should contact<\/strong> your doctor immediately.<\/strong> List of reported side effect s<\/strong><\/p>\n\n\n\n The following list is a list of side effects that have been reported and that may be related to the injection procedure or the medicine. Do not be afraid, you may not be affected by any of these. Always discuss suspected side effects with your doctor. Very common side effects are <\/strong>(may affect more than 1 in 10 people):<\/em><\/p>\n\n\n\n Common side effects are <\/strong>(may affect up to 1 in 10 people):<\/em><\/p>\n\n\n\n * Conditions associated with wet AMD only observed in patients with wet AMD Less common side effects are <\/strong>(may affect up to 1 in 100 people):<\/em><\/p>\n\n\n\n Rare <\/strong>side effects are <\/strong>(may affect up to 1 in 1000 people):<\/em><\/p>\n\n\n\n In clinical trials, an increased incidence of bleeding from small blood vessels in the outer layer of the eye ( conjunctival hemorrhage) has been reported in patients with wet AMD receiving blood thinners. The increased incidence was similar between patients treated with ranibizumab and Eylea. Systemic use of VEGF inhibitors, compounds similar to those found in Eylea, are possibly associated with an increased risk of blood clots that block blood vessels (arterial thromboembolic events) and it can lead to a heart attack or stroke ( stroke ). There is a theoretical risk of such events after the injection of Eylea into the eye. As with all therapeutic proteins, there is a risk of an immune reaction ( antibody formation ) with Eylea. Eylea is an injection solution ( injection ) in a vial (4 mg \/ 100 microliters). The solution is colorless to pale yellow. Pack size of 1 vial + 1 filter needle.<\/p>\n\n\n\n Bayer AG Manufacturer<\/strong> Contact the representative of the marketing authorization holder to find out more about this medicine:<\/p>\n","protected":false},"excerpt":{"rendered":" 40 mg\/ml solution for injection in a vial of
<\/p>\n\n\n\n
<\/li><\/ul>\n\n\n\nChildren and young people<\/h2>\n\n\n\n
Other medicines and Eylea<\/h2>\n\n\n\n
Pregnancy and breastfeeding<\/h2>\n\n\n\n
<\/li>
<\/li>Driving and using machines<\/h2>\n\n\n\n
Important information about some of the ingredients of Eylea<\/h2>\n\n\n\n
<\/p>\n\n\n\n3. How to get Eylea<\/h2>\n\n\n\n
<\/p>\n\n\n\n
Eylea is given as an injection into the eye (intravitreal injection ).
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\nIf you fail to give you a dose of Eylea<\/h2>\n\n\n\n
Before stopping treatment with Eylea<\/h2>\n\n\n\n
<\/p>\n\n\n\n4. Possible side effects<\/h2>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/li><\/ul>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n5. How to store Eylea<\/h2>\n\n\n\n
6. Contents of the packaging and other information<\/h2>\n\n\n\n
Content declaration<\/h2>\n\n\n\n
What the medicine looks like and the contents of the pack<\/h2>\n\n\n\n
<\/p>\n\n\n\nMarketing Authorisation Holder<\/h2>\n\n\n\n
51368 Leverkusen
Germany
<\/p>\n\n\n\n
Bayer AG
M\u00fcllerstra\u00dfe 178
13353 Berlin
Germany
<\/p>\n\n\n\n
\naflibercept<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2205,2200],"tags":[3264,3266,3267,3265,3268,3270,3271,3269,2215,2212],"class_list":["post-8578","post","type-post","status-publish","format-standard","hentry","category-e","category-medicines","tag-aflibercept","tag-aflibercept-dose","tag-aflibercept-side-effects","tag-aflibercept-uses","tag-eylea","tag-eylea-dose","tag-eylea-side-effects","tag-eylea-uses","tag-injection","tag-medicine"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/8578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=8578"}],"version-history":[{"count":4,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/8578\/revisions"}],"predecessor-version":[{"id":9865,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/8578\/revisions\/9865"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=8578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=8578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=8578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}